Oceantech Acquisitions I Corp (OTEC): * Oceantech Acquisitions I Corp (OTEC). AND CAPTURA BIOPHARMA, INC. ANNOUNCE SIGNING OF DEFINITIVE BUSINESS COMBINATION AGREEMENT. * Oceantech Acquisitions I Corp (OTEC) - COMBINED COMPANY WOULD HAVE AN APPROXIMATE POST-TRANSACTION EQUITY MARKET CAPITALIZATION OF $224.3 MILLION Source text for Eikon: Further company coverage:
Bristol Myers Squibb Co (BMY) on Wednesday reported bigger second-quarter profit than expected as sales of its blockbuster cancer drug Revlimid did not drop as steeply as feared despite competition from generic drugs. The U.S. drugmaker cut its annual sales forecast slightly to $46 billion due to the impact of the strong dollar, sending its shares down 2.7% to $71.72 before the opening bell.
Bristol Myers Squibb Co (BMY) on Wednesday reported higher-than-expected second-quarter profit as a dropoff in sales of its blockbuster cancer drug Revlimid, which now faces generic competition, was not as steep as projected. The company cut its full year sales forecast slightly to $46 billion due to the impact of the strong dollar from $46.39 billion.
Larkspur Health Acquisition Corp (LSPR) : * ZYVERSA THERAPEUTICS TO BECOME A PUBLICLY TRADED BIOPHARMA COMPANY VIA MERGER WITH Larkspur Health Acquisition Corp (LSPR). * Larkspur Health Acquisition Corp (LSPR) - COMBINED COMPANY TO HAVE AN IMPLIED INITIAL ENTERPRISE VALUE OF APPROXIMATELY $108.92 MILLION.
Theravance Biopharma Inc (TBPH): * PRESS RELEASE - THERAVANCE BIOPHARMA TO SELL TRELEGY ELLIPTA ROYALTY INTERESTS TO ROYALTY PHARMA FOR APPROXIMATELY $1.1 BILLION IN UPFRONT CASH WITH OVER $1.5 BILLION IN POTENTIAL TOTAL VALUE. * THERAVANCE BIOPHARMA (TBPH) - ROYALTY PHARMA TO INVEST UP TO $40 MILLION TO ADVANCE DEVELOPMENT OF AMPRELOXETINE IN MULTIPLE SYSTEM ATROPHY.
Galapagos NV: * REG-GALAPAGOS TO ACQUIRE CELLPOINT AND ABOUNDBIO TO ACCELERATE ACCESS TO NEXT-GENERATION CELL THERAPIES. * GALAPAGOS NV - ALLCASH ACQUISITION OFCELLPOINT FOR UPFRONT AMOUNT OF EUR 125 MILLION, WITH MILESTONE PAYMENTS UP TO EUR 100 MILLION & ABOUNDBIO FOR $14 MILLION.
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
Log In Required
Line of Credit Log In Required